Sorrento, NantWorks deal

NantWorks will acquire the Igdrasol Inc. subsidiary of Sorrento for $90 million up front and up to $1.2 billion in regulatory and commercial milestones. NantWorks will gain cancer drug Cynviloq. Sorrento will receive transfer pricing payments in excess of cost and for three years following the deal close will have an option to co-develop and co-commercialize the injectable nanoparticle formulation of paclitaxel. ...